Clinical Digest: A Comprehensive Review of Recent Astrazeneca Patents
This compilation provides an overview of Astrazeneca‘s latest patent inventions. Alongside these patents are potentially related patents, which may include work from Astrazeneca or other entities exploring similar therapeutic areas. This resource aims to offer researchers, clinicians, investors, and the broader public insights into Astrazeneca’s current research and development pipeline. By presenting patent details alongside related intellectual property (regardless of origin), this compilation facilitates a broader understanding of Astrazeneca’s strategic focus and how it potentially compares to direct and indirect competitors in these therapeutic spaces. This information can be valuable for identifying emerging trends in drug development, assessing the commercial potential of specific research programs, and understanding the broader landscape of scientific contributions related to Astrazeneca’s patent inventions. (Last updated on: 2025-05-22)
This curated list is brought to you by the Clinical Digest Team. Experience the cutting-edge capabilities of Clinical Digest, an innovative AI-powered clinical research platform that gets you the personalized and comprehensive updates on the latest clinical research in your field. It also empowers you to read articles, write articles, conduct literature reviews and generate research reports.
Experience the full potential of our services today!
TABLE 1: Clinical Digest: A Comprehensive Review of Recent Astrazeneca Patents
| Title | Applicant/Assignee | Filing Date | Publish Date | Grant Date | |
|---|---|---|---|---|---|
| 1 | METHODS OF TREATING CHRONIC KIDNEY DISEASE WITH DAPAGLIFLOZIN Related Patents View Abstract: The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as … |
ASTRAZENECA | 2024-12-11 | 2025-05-22 | |
| 2 | Cell Therapy Related Patents View Abstract: Populations of cells for use in the treatment of heart disease and methods of making the same. … |
ASTRAZENECA | 2024-09-16 | 2025-05-22 | |
| 3 | COMPRESSIBLE SODIUM CAPRATE FORMULATIONS Related Patents View Abstract: The present disclosure provides a method of making an oral tablet comprising mixing a macromolecule with sodium caprate to form a mixture, and compressing the mixture into a … |
ASTRAZENECA | 2023-02-21 | 2025-05-15 | |
| 4 | METHODS OF TREATING PROSTATE CANCER Related Patents View Abstract: This disclosure relates to methods of treating prostate cancer in a subject. This disclosure more specifically relates to methods for treating prostate cancer, such as metastatic … |
ASTRAZENECA | 2023-02-14 | 2025-05-01 | |
| 5 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-STEAP2 CHIMERIC ANTIGEN RECEPTOR T CELLS Related Patents View Abstract: The disclosure provides therapeutic combinations of chimeric antigen receptor T cells that specifically bind human STEAP2 (e.g., AZD0754) with androgen receptor antagonists (e.g., … |
ASTRAZENECA | 2024-09-25 | 2025-04-17 | |
| 6 | TREATMENT OF LUPUS Related Patents View Abstract: The disclosure relates to methods and compositions for the treatment of Systemic Lupus Erythematosus (SLE). … |
ASTRAZENECA | 2022-10-03 | 2025-04-17 | |
| 7 | COMBINATIONS WITH MODULATORS OF PNPLA3 EXPRESSION Related Patents View Abstract: Provided are methods of treating a liver disease in a subject, comprising administering to the subject: i) an inhibitor of patatin like phospholipase domain containing 3 (PNPLA3) … |
ASTRAZENECA | 2022-06-07 | 2025-04-17 | |
| 8 | T CELL BINDING COMPOSITIONS AND METHODS Related Patents View Abstract: The disclosure generally relates to binding proteins that comprise antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site. The … |
ASTRAZENECA | 2024-10-09 | 2025-04-10 | |
| 9 | METHODS OF IMPROVING PROTEIN EXPRESSION Related Patents View Abstract: The present disclosure relates to nucleic acids that comprise a nucleotide sequence encoding an immunoglobulin heavy chain, wherein the nucleotide sequences of at one or two … |
ASTRAZENECA | 2023-01-10 | 2025-04-10 | |
| 10 | CERTAIN 2,5-DIAZABICYCLO[4.2.0]OCTANES AND OCTAHYDROFURO[3,4-B]PYRAZINES AS GLP-1 RECEPTOR MODULATORS Related Patents View Abstract: There are disclosed certain 2,5-diazabicyclo[4.2.0]octanes of formula (I) and octahydrofuro[3,4-b]pyrazines, and pharmaceutically acceptable salts thereof, together with … |
ASTRAZENECA | 2022-10-04 | 2025-04-10 | |
| 11 | PHARMACEUTICAL COMPOSITIONS COMPRISING (2S)-N-{(1S)-1-CYANO-2-[4-(3-METHYL-2-OXO-2,3-DIHYDRO-1,3-BENZOXAZOL-5-yl)PHENYL]ETHYL}-1,4- OXAZEPANE-2-CARBOXAMIDE Related Patents View Abstract: The present disclosure relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical … |
ASTRAZENECA | 2024-12-09 | 2025-04-03 | |
| 12 | COMBINATION OF EGFR INHIBITOR AND MEK INHIBITOR FOR USE IN THE TREATMENT OF NRAS MUTATED CANCER Related Patents View Abstract: The invention relates to the methods for identifying resistance to cancer therapy, by identification of an E63K NRAS mutation, a G12V NRAS mutation or a gain of copy number of … |
ASTRAZENECA | 2024-01-17 | 2025-04-03 | |
| 13 | METHODS OF TREATING PREDIABETES OR REDUCING THE RISK OF DEVELOPING TYPE 2 DIABETES WITH DAPAGLIFLOZIN Related Patents View Abstract: The present disclosure is directed to methods of reducing the risk of developing Type 2 diabetes and/or treating prediabetes in a patient in need thereof, the method comprising … |
ASTRAZENECA | 2023-01-25 | 2025-04-03 | |
| 14 | TREATMENT OF GASTRIC CANCER AND/OR GASTROESOPHAGEAL JUNCTION CANCER Related Patents View Abstract: The disclosure relates to methods and compositions for treating patients with resectable gastric cancer and/or gastroesophageal junction cancer using durvalumab and chemotherapy. … |
ASTRAZENECA | 2024-09-20 | 2025-03-27 | |
| 15 | ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY Related Patents View Abstract: The invention provides anti-IFNAR antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies. … |
ASTRAZENECA | 2023-02-27 | 2025-03-27 | |
| 16 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS Related Patents View Abstract: The present disclosure relates to methods of treating a brain tumour or a neuroblastoma in a patient in need thereof, the method comprising administering to the patient a … |
ASTRAZENECA | 2022-12-20 | 2025-03-13 | |
| 17 | CONJUGATES COMPRISING CLEAVABLE LINKERS Related Patents View Abstract: The specification relates to conjugates comprising a linker of Formula (IMA): and pharmaceutically acceptable salts thereof. The specification also relates the use of the … |
ASTRAZENECA | 2024-08-14 | 2025-03-06 | |
| 18 | MULTIVALENT CARGO-CARRYING COMPLEXES AND USES THEREOF Related Patents View Abstract: Provided are multivalent saccharide-containing compounds which are bonded to nucleic acids. These compounds contain a shikimic acid-derived core and are useful for delivering … |
ASTRAZENECA | 2024-07-23 | 2025-02-27 | |
| 19 | CERTAIN 3-AZABICYCLO[3.1.0]HEXANES AS GLP-1 RECEPTOR MODULATORS Related Patents View Abstract: There are disclosed certain 3-azabicyclo[3.1.0]hexanes, and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The … |
ASTRAZENECA | 2022-12-15 | 2025-02-27 | |
| 20 | CONJUGATES COMPRISING CLEAVABLE LINKERS Related Patents View Abstract: The specification relates to conjugates comprising a linker of Formula (IA): and pharmaceutically acceptable salts thereof. The specification also relates the use of the … |
ASTRAZENECA | 2024-08-14 | 2025-02-20 | |
| 21 | COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY Related Patents View Abstract: 1. A pharmaceutical composition deliverable from a metered dose inhaler, the pharmaceutical composition comprising: a propellant of pharmaceutical grade 1,1-Difluoroethane … |
ASTRAZENECA | 2022-12-16 | 2025-02-20 | |
| 22 | CD123 ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THE SAME Related Patents View Abstract: The present disclosure generally relates to antibodies, antigen binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the α chain of the … |
ASTRAZENECA | 2024-07-26 | 2025-02-13 | |
| 23 | MULTIVALENT CARGO-CARRYING COMPLEXES AND USES THEREOF Related Patents View Abstract: Provided are multivalent saccharide-containing compounds which are bonded to nucleic acids. These compounds comprise one or more nitrogen-modified phosphate groups which link the … |
ASTRAZENECA | 2024-07-23 | 2025-02-13 | |
| 24 | RSV VACCINE Related Patents View Abstract: Provided herein is a vaccine against RSV. The vaccine comprises an mRNA encoding a stabilised prefusion RSV F protein immunogen linked to a scaffold based on lumazine synthase. … |
ASTRAZENECA | 2024-07-18 | 2025-02-06 | |
| 25 | CERTAIN 3-AZABICYCLO[3.1.0]HEXANES AS GLP-1 RECEPTOR MODULATORS Related Patents View Abstract: There are disclosed certain 3-azabicyclo[3.1.0]hexanes, and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The … |
ASTRAZENECA | 2022-12-15 | 2025-02-06 | |
| 26 | COMPOSITIONS AND METHODS FOR IMPROVING THE EFFICACY OF CAS9-BASED KNOCK-IN STRATEGIES Related Patents View Abstract: The present disclosure provides a non-naturally occurring CRISPR-Cas system comprising: a Cas9 effector protein capable of generating cohesive ends (stiCas9), and a guide … |
ASTRAZENECA | 2024-02-13 | 2025-01-30 | |
| 27 | PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291 Related Patents View Abstract: The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical … |
ASTRAZENECA | 2024-09-26 | 2025-01-16 | |
| 28 | AMIDO HETEROAROMATIC COMPOUNDS Related Patents View Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to … |
ASTRAZENECA | 2024-09-13 | 2025-01-09 | |
| 29 | PHARMACEUTICAL COMPOSITION Related Patents View Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid … |
ASTRAZENECA et. al. | 2024-09-03 | 2025-01-02 | |
| 30 | TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOUS Related Patents View Abstract: The disclosure relates to methods and compositions for the treatment of Cutaneous Lupus Erythematous (CLE). Specifically, the disclosure relates to methods comprising … |
ASTRAZENECA | 2024-02-07 | 2025-01-02 | |
| 31 | INHIBITOR OF TYPE 1 INTERFERON RECEPTOR STEROID SPARING IN SYSTEMIC LUPUS ERYTHERMATOSUS PATIENTS Related Patents View Abstract: The disclosure relates to methods and compositions for the treatment of Systemic Lupus Erythematosus (SLE). … |
ASTRAZENECA | 2022-05-11 | 2025-01-02 | |
| 32 | TREATMENT OF LUPUS NEPHRITIS WITH ANTI-TYPE I INF RECEPTOR ANTIBODY ANIFROLUMAB Related Patents View Abstract: The disclosure relates to methods and compositions for the treatment of lupus nephritis (LN) with anti-type I IFN receptor inhibitor antibody Anifrolumab. Results of clinical … |
ASTRAZENECA | 2022-04-22 | 2025-01-02 | |
| 33 | PHARMACEUTICAL COMPOSITION Related Patents View Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid … |
ASTRAZENECA et. al. | 2024-09-03 | 2024-12-26 | |
| 34 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS Related Patents View Abstract: The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or … |
ASTRAZENECA | 2024-08-28 | 2024-12-26 | |
| 35 | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL LUNG CANCER Related Patents View Abstract: The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the adjuvant treatment after tumour resection of patients with … |
ASTRAZENECA | 2024-04-15 | 2024-12-26 | |
| 36 | CERTAIN 2,5-DIAZABICYCLO[4.2.0]OCTANES AS GLP-1 RECEPTOR MODULATORS Related Patents View Abstract: There are disclosed certain 2,5-diazabicyclo[4.2.0]octanes of formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use … |
ASTRAZENECA | 2022-10-04 | 2024-12-19 | |
| 37 | METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN AN ENHANCED PATIENT POPULATION USING BENRALIZUMAB Related Patents View Abstract: Provided herein is are methods of treating Chronic Obstructive Pulmonary Disease (COPD) in a patient, comprising administering to the patient an effective amount of benralizumab … |
ASTRAZENECA | 2024-08-27 | 2024-12-12 | |
| 38 | Use of Inhibitors to Increase Efficiency of Crispr/CAS Insertions Related Patents View Abstract: The present disclosure provides methods of inserting a polynucleotide of interest into the genome of a eukaryotic cell, wherein said methods comprise improving the efficiency of … |
ASTRAZENECA | 2023-04-06 | 2024-12-12 | |
| 39 | PEPTIDE DENDRONS AND METHODS OF USE THEREOF Related Patents View Abstract: The specification relates to peptide dendrons comprising one or more residues derived from a modified lysine of formula (I), pharmaceutical delivery systems comprising these … |
ASTRAZENECA | 2022-10-07 | 2024-12-12 | |
| 40 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS Related Patents View Abstract: The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for … |
ASTRAZENECA et. al. | 2024-08-07 | 2024-12-05 | |
| 41 | ANTI-IFNAR1 DOSING REGIME FOR SUBCUTANEOUS INJECTION Related Patents View Abstract: The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease. Specifically, the disclosure relates to a subcutaneous dose of a type I IFN … |
ASTRAZENECA | 2024-05-15 | 2024-12-05 | |
| 42 | METHODS OF TREATING INFLAMMATORY DISEASES WITH A SELECTIVE GLUCOCORTICOID RECEPTOR MODULATOR Related Patents View Abstract: This disclosure relates to methods for treating a chronic inflammatory disease or disorder in a subject having type 2 diabetes mellitus or being predisposed to type 2 diabetes … |
ASTRAZENECA | 2022-09-16 | 2024-12-05 | |
| 43 | Devices and a System for Detection and Analysis of Inhaler Use Related Patents View Abstract: Devices, methods and a system for detection and analysis of inhaler use, in particular breath detection modules and inhaler device counters. An electronic inhaler counter device ( … |
ASTRAZENECA | 2022-06-27 | 2024-11-28 | |
| 44 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 Related Patents View Abstract: There are disclosed certain 2,4,6-trisubstituted 1,3,5-triazine compounds of Formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them … |
ASTRAZENECA | 2024-07-24 | 2024-11-21 | |
| 45 | CHEMICAL COMPOUNDS Related Patents View Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to … |
ASTRAZENECA | 2024-07-17 | 2024-11-21 | |
| 46 | COMPOUNDS AND THEIR USE Related Patents View Abstract: The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R , R , R , R , R , W, X, Y, and Z have the meanings defined … |
ASTRAZENECA et. al. | 2024-03-21 | 2024-11-21 | |
| 47 | CA S9 EFFECTOR PROTEINS WITH ENHANCED STABILITY Related Patents View Abstract: Provided are Cas9 effector proteins having enhanced stability. Embodiments of the Cas9 effector proteins have a first nuclear localization signal attached to the N-terminus and a … |
ASTRAZENECA | 2022-05-26 | 2024-11-21 | |
| 48 | COMPOSITIONS AND METHODS FOR TREATING LATE STAGE LUNG CANCER Related Patents View Abstract: Disclosed are methods for treating extensive-stage small-cell lung cancer (ES-SCLC) with an antibody that inhibits PD1/PD-L1 activity in combination with etoposide and a … |
ASTRAZENECA | 2024-05-07 | 2024-11-14 | |
| 49 | IRAK4 PROTACS Related Patents View Abstract: This specification relates to compounds according to Formula (I), which are of PROTACs of IRAK4, to pharmaceutical compositions containing them, and to their use in therapy for … |
ASTRAZENECA | 2024-04-03 | 2024-11-14 | |
| 50 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Related Patents View Abstract: There are disclosed certain substituted pyrazine-2-carboxamides of Formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their … |
ASTRAZENECA | 2022-07-19 | 2024-11-14 | |
| 51 | CONJUGATES COMPRISING CLEAVABLE LINKERS Related Patents View Abstract: The specification relates to conjugates comprising a linker of Formula (ICA): and pharmaceutically acceptable salts thereof. The specification also relates the use of the … |
ASTRAZENECA | 2024-04-09 | 2024-11-07 | |
| 52 | CONJUGATES COMPRISING CLEAVABLE LINKERS Related Patents View Abstract: The specification relates to conjugates comprising a linker of Formula (IA): and pharmaceutically acceptable salts thereof. The specification also relates the use of the … |
ASTRAZENECA | 2024-04-09 | 2024-11-07 | |
| 53 | POLQ INHIBITORS Related Patents View Abstract: The specification generally relates to compounds of Formula (I): or a stereoisomer or pharmaceutically salt thereof, wherein G, G , G , X, Y, R , R , Q , Q , and Q have any of the … |
ASTRAZENECA | 2023-12-05 | 2024-11-07 | |
| 54 | COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES Related Patents View Abstract: The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor … |
ASTRAZENECA | 2024-07-05 | 2024-10-31 | |
| 55 | ANTIBODY MOLECULES AND CONJUGATES Related Patents View Abstract: The present disclosure relates to antibody molecules that bind epidermal growth factor receptor (EGFR) and/or c-Met and conjugates containing these antibody molecules. The … |
ASTRAZENECA | 2024-06-25 | 2024-10-31 | |
| 56 | DOSE Related Patents View Abstract: The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease. Specifically, the disclosure relates to a subcutaneous dose of a type I IFN … |
ASTRAZENECA | 2024-02-27 | 2024-10-31 | |
| 57 | COMPOSITIONS AND METHODS OF TREATING DISEASE WITH CHIMERIC ANTIGEN RECEPTORS TO B CELL MATURATION ANTIGEN (BCMA) Related Patents View Abstract: This disclosure relates to compositions and methods for treating disease using chimeric antigen receptor cells and/or antigen binding domains targeting BCMA. … |
ASTRAZENECA | 2024-02-21 | 2024-10-24 | |
| 58 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS Related Patents View Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that … |
ASTRAZENECA | 2024-06-17 | 2024-10-10 | |
| 59 | 1-[2-(AMINOMETHYL)BENZYL]-2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES AS INHIBITORS OF MYELOPEROXIDASE Related Patents View Abstract: There are disclosed certain 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one compounds of formula (I), and pharmaceutically acceptable salts … |
ASTRAZENECA | 2024-04-05 | 2024-10-10 | |
| 60 | DOSING REGIMEN Related Patents View Abstract: A method of treatment or prophylaxis of diseases or conditions in which inhibition of PARP1 is beneficial, comprising administering to the subject AZD5305 in a daily dose of 10 to … |
ASTRAZENECA | 2024-03-27 | 2024-10-03 | |
| 61 | STEROID SPARING Related Patents View Abstract: The disclosure relates to methods and compositions for the treatment of Systemic Lupus Erythematosus (SLE). Specifically, the disclosure relates to methods comprising … |
ASTRAZENECA | 2021-11-17 | 2024-10-03 | |
| 62 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS Related Patents View Abstract: The present application relates to novel compounds of formula (I) to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to … |
ASTRAZENECA | 2024-05-21 | 2024-09-26 | |
| 63 | METHODS FOR GENERATING PRIMARY IMMUNE CELLS Related Patents View Abstract: The disclosure relates to methods, cells, and compositions for preparing cell populations and compositions for adoptive cell therapy. In particular, provided herein are methods … |
ASTRAZENECA | 2024-02-21 | 2024-09-26 | |
| 64 | COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF PROTEINURIA CHRONIC KIDNEY DISEASE Related Patents View Abstract: Methods for treating high proteinuria chronic kidney disease and/or at least one disease, disorder, or condition associated therewith in patients by the use of a fixed-dose … |
ASTRAZENECA | 2024-02-07 | 2024-09-19 | |
| 65 | IRAK4 Inhibitors Related Patents View Abstract: The present application relates to chemical compounds of Formula (1), and pharmaceutically acceptable salts thereof, that inhibit IRAK4 and consequently have potential utility in … |
ASTRAZENECA | 2024-03-21 | 2024-09-12 | |
| 66 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF Related Patents View Abstract: The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor. … |
ASTRAZENECA et. al. | 2024-02-23 | 2024-09-05 | |
| 67 | CONTROL OF MULTI-GENE EXPRESSION USING SYNTHETIC PROMOTERS Related Patents View Abstract: The invention relates to expression vectors comprising mammalian synthetic promoters that can mediate expression of multiple genes at predictable relative stoichiometries. … |
ASTRAZENECA | 2022-03-15 | 2024-09-05 | |
| 68 | NUCLEIC ACID MOLECULES Related Patents View Abstract: The present disclosure relates to a nucleic acid molecule comprising 5′-UTR and/or 3′-UTR sequences that yield high translation levels. Aspects of the disclosure further relate to … |
ASTRAZENECA | 2024-01-19 | 2024-08-22 | |
| 69 | VACCINE Related Patents View Abstract: The present disclosure relates to methods of inducing a pan-sarbecoronavirus variant immune response for the treatment and prevention of coronavirus infections. … |
ASTRAZENECA | 2024-01-19 | 2024-08-22 | |
| 70 | COMPOSITIONS AND METHODS FOR TREATING ALPHA-SYNUCLEINOPATHIES Related Patents View Abstract: The invention provides a method for treating or preventing an a-synucleinopathy in a subject in need thereof, the method comprising administering to the subject a fixed dose of … |
ASTRAZENECA et. al. | 2023-12-28 | 2024-08-22 | |
| 71 | SPIROCYCLIC COMPOUNDS Related Patents View Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their … |
ASTRAZENECA | 2024-02-16 | 2024-08-15 | |
| 72 | METHODS OF TREATING BREAST CANCER Related Patents View Abstract: This disclosure relates to methods for the adjuvant treatment of a subject having germline mutated BRCA1 and/or BRCA2 breast cancer, wherein the subject has previously received … |
ASTRAZENECA | 2022-05-31 | 2024-08-15 | |
| 73 | PHARMACEUTICAL COMPOSITIONS COMPRISING (2S)-N-{(1S)-1-CYANO-2-[4-(3-METHYL-2-OXO-2,3-DIHYDRO-1,3-BENZOXAZOL-5-yl)PHENYL]ETHYL}-1,4- OXAZEPANE-2-CARBOXAMIDE Related Patents View Abstract: The present disclosure relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical … |
ASTRAZENECA | 2024-03-28 | 2024-08-01 | |
| 74 | Computer System and Method for Generating Trigger Alerts to Maximize Interactions With Healthcare Providers Related Patents View Abstract: A pharmaceutical company may employ a computer system that is configured to analyze anonymized patient data for patients treated by each of a plurality of healthcare providers … |
ASTRAZENECA | 2024-01-08 | 2024-08-01 | |
| 75 | COMPOSITIONS AND METHODS FOR TREATING LUNG CANCER Related Patents View Abstract: Disclosed are methods for treating locally advanced (Stage III), unresectable non-small-cell lung cancer (NSCLC) with an antibody that inhibits PD-1/PD-L1 activity concurrently … |
ASTRAZENECA | 2022-05-24 | 2024-08-01 | |
| 76 | 2,6,9-TRISUBSTITUTED PURINES Related Patents View Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein R , R , R , R , and R are as defined in the specification; pharmaceutical … |
ASTRAZENECA | 2023-12-15 | 2024-07-25 | |
| 77 | METHODS OF TREATING HOMOLOGOUS RECOMBINATION DEFICIENT CANCER Related Patents View Abstract: This disclosure relates to methods of treating homologous recombination (HR) deficient cancers, such as ovarian cancer, fallopian tube cancer, primary peritoneal cancer, breast … |
ASTRAZENECA | 2024-03-29 | 2024-07-18 | |
| 78 | METHODS AND COMBINATIONS FOR THE TREATMENT OF CANCER USING IMMUNE CHECKPOINT INHIBITOR ANTIBODIES Related Patents View Abstract: The disclosure relates to methods, compositions, and combinations for the treatment of cancer. Specifically, the disclosure relates to methods comprising administering to a … |
ASTRAZENECA | 2024-03-28 | 2024-07-18 | |
| 79 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF Related Patents View Abstract: A compound with the Formula (I): and … |
ASTRAZENECA | 2023-12-14 | 2024-07-18 | |
| 80 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF Related Patents View Abstract: A compound with the Formula (I): A-B-C (I) wherein A is of the following formula: where X is N B is of formula (B-1) or (B-2) and C is selected from the group consisting of … |
ASTRAZENECA | 2023-09-20 | 2024-07-11 | |
| 81 | METHODS OF TREATING HEART FAILURE WITH REDUCED EJECTION FRACTION Related Patents View Abstract: The present disclosure is directed to methods of treating patients with heart failure with reduced ejection fraction (HFrEF), with and without Type 2 diabetes, with an SGLT2 … |
ASTRAZENECA | 2024-01-11 | 2024-07-04 | |
| 82 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF Related Patents View Abstract: A compound with the Formula (I): A-B—C (I) … |
ASTRAZENECA | 2023-09-20 | 2024-07-04 | |
| 83 | JAK1 SELECTIVE INHIBITORS Related Patents View Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R -R have any of the meanings defined herein. Also disclosed are … |
ASTRAZENECA | 2023-12-13 | 2024-06-27 | |
| 84 | TREATMENT OF AUTOIMMUNE DISEASE Related Patents View Abstract: Antibodies for binding PADs and their use in therapy. … |
ASTRAZENECA | 2023-12-18 | 2024-06-20 | |
| 85 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 Related Patents View Abstract: There are disclosed certain 2,4,6-trisubstituted 1,3,5-triazine compounds of Formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them … |
ASTRAZENECA | 2023-10-18 | 2024-06-20 | |
| 86 | COMBINATION TREATMENT FOR MELANOMA Related Patents View Abstract: Combination Treatments for Melanoma This specification discloses the use of an ATR inhibitor in combination with an immune checkpoint inhibitor for the treatment of melanoma in a … |
ASTRAZENECA | 2022-03-25 | 2024-06-20 | |
| 87 | PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291 Related Patents View Abstract: The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical … |
ASTRAZENECA | 2021-09-17 | 2024-06-13 | |
| 88 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS Related Patents View Abstract: The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or … |
ASTRAZENECA | 2024-01-08 | 2024-06-06 | |
| 89 | SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORS Related Patents View Abstract: The present application relates to chemical compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit IRAK4 and consequently have potential utility in … |
ASTRAZENECA | 2023-11-02 | 2024-06-06 | |
| 90 | METHODS OF TREATMENT OF BREAST CANCER Related Patents View Abstract: The present specification relates methods of treatment of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2−), metastatic or loco-regionally … |
ASTRAZENECA | 2023-10-23 | 2024-06-06 | |
| 91 | COMPOSITIONS AND METHODS FOR SITE-SPECIFIC MODIFICATION Related Patents View Abstract: The present disclosure provides a polynucleotide comprising an RNA guide sequence, a Cas-binding region, and a DNA template sequence. The disclosure also provides compositions … |
ASTRAZENECA | 2022-04-06 | 2024-06-06 | |
| 92 | SYSTEM AND METHOD FOR ONLINE DETECTION OF A POST-TRANSLATIONAL MODIFICATION OF A POLYPEPTIDE Related Patents View Abstract: Provided herein is a method and system for monitoring a post-translational modification and glycosylation of a polypep-tide, and in particular, to an online i.e. automated method … |
ASTRAZENECA | 2022-03-15 | 2024-06-06 | |
| 93 | FORMULATION COMPRISING CERALASERTIB Related Patents View Abstract: A pharmaceutical formulation which comprises ceralasertib, dibasic calcium phosphate, microcrystalline cellulose, low-substituted hydroxypropyl cellulose and magnesium stearate is … |
ASTRAZENECA | 2022-03-21 | 2024-05-30 | |
| 94 | INHIBITORS OF MYELOPEROXIDASE Related Patents View Abstract: The specification generally relates to compounds of Formula (I), (Ia), and (Ib): … |
ASTRAZENECA | 2023-08-17 | 2024-05-23 | |
| 95 | APPARATUS AND METHOD FOR EVALUATING PHYSICAL STRENGTH OR ROBUSTNESS OF SOLID PHARMACEUTICAL DOSAGE FORMS BASED ON AN IMPACT STRIKE TEST Related Patents View Abstract: A solid pharmaceutical dosage form testing apparatus and a method are presented. The solid pharmaceutical dosage form testing apparatus includes a striker component, an impact … |
ASTRAZENECA | 2022-04-08 | 2024-05-23 | |
| 96 | COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS Related Patents View Abstract: This disclosure relates to compositions and methods for treating cancer using armored chimeric antigen receptor cells. … |
ASTRAZENECA | 2024-01-24 | 2024-05-16 | |
| 97 | OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER Related Patents View Abstract: The specification relates to osimertinib or a pharmaceutically acceptable salt thereof for use in the treatment of patients with locally advanced unresectable epidermal growth … |
ASTRAZENECA | 2024-01-16 | 2024-05-16 | |
| 98 | TREATMENT OF CARDIOMETABOLIC DISEASE WITH INHIBITORS OF TYPE I INTERFERON SIGNALLING Related Patents View Abstract: The disclosure relates to methods for the treatment of, or for reducing the risk for development of, a cardiometabolic in a patient using an inhibitor of type I IFN signalling. … |
ASTRAZENECA | 2023-12-22 | 2024-05-16 | |
| 99 | METHOD OF TREATING FATTY LIVER DISEASE Related Patents View Abstract: The present disclosure provides methods of treating or preventing fatty liver disease and/or lowering cholesterol and LDL cholesterol levels in a subject. The present disclosure … |
ASTRAZENECA et. al. | 2023-11-02 | 2024-05-16 | |
| 100 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER Related Patents View Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where R , A , A and A have any of the meanings defined herein. The … |
ASTRAZENECA et. al. | 2023-12-14 | 2024-05-09 | |
| 101 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS Citation: 1 Related Patents View Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that … |
ASTRAZENECA | 2023-12-08 | 2024-04-25 | |
| 102 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer Related Patents View Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where R and R have any of the meanings defined herein. The … |
ASTRAZENECA | 2023-07-10 | 2024-04-18 | |
| 103 | THERAPEUTIC DENDRIMERS Related Patents View Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and … |
ASTRAZENECA | 2023-06-14 | 2024-04-11 | |
| 104 | HETEROAROMATIC COMPOUNDS Related Patents View Abstract: The specification relates to compounds of Formula (1): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to … |
ASTRAZENECA | 2023-04-27 | 2024-04-11 | |
| 105 | PROTEIN KINASE B INHIBITORS Related Patents View Abstract: The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z , Z , R , R , R and n are as described in the specification, which may be useful … |
ASTRAZENECA | 2023-08-04 | 2024-04-04 | |
| 106 | CLINICAL ENDPOINT ADJUDICATION SYSTEM AND METHOD Related Patents View Abstract: The present disclosure relates to a system and method for use in performing clinical endpoint adjudication to provide: efficient, automated clinical event classification and … |
ASTRAZENECA | 2022-01-25 | 2024-03-28 | |
| 107 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES Related Patents View Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X , R , R , R , R , R and R are as defined in the specification; … |
ASTRAZENECA | 2021-12-16 | 2024-03-28 | |
| 108 | PHARMACEUTICAL FORMULATIONS Related Patents View Abstract: A pharmaceutical formulation which comprises Compound 1, one or more pharmaceutical fillers, one or more pharmaceutical disintegrants, and one or more pharmaceutical lubricant. … |
ASTRAZENECA | 2023-08-30 | 2024-03-21 | |
| 109 | PHARMACEUTICAL PROCESS AND INTERMEDIATES Related Patents View Abstract: There is provided a new and improved synthetic route for the synthesis of the compound … |
ASTRAZENECA | 2023-08-18 | 2024-03-21 | |
| 110 | METHODS OF TREATING HEART FAILURE WITH PRESERVED EJECTION FRACTION EMPLOYING DAPAGLIFLOZIN AND COMPOSITIONS COMPRISING THE SAME Related Patents View Abstract: Methods for treating and/or preventing HFpEF and/or at least one disease, disorder, and/or condition associated therewith in patients by the use of dapagliftozin and compositions … |
ASTRAZENECA | 2023-10-19 | 2024-03-14 | |
| 111 | GRAPH CONSTRUCTION AND VISUALIZATION OF MULTIPLEX IMMUNOFLUORESCENCE IMAGES Related Patents View Abstract: Provided herein are system, apparatus, article of manufacture, method and/or computer program product embodiments, and/or combinations and sub-combinations thereof, for providing … |
ASTRAZENECA | 2022-01-11 | 2024-02-29 | |
| 112 | COMBINATION THERAPIES FOR TREATMENT OF CIRRHOSIS WITH PORTAL HYPERTENSION Related Patents View Abstract: A method of treating liver cirrhosis in a subject in need thereof. The method includes administering to the subject a composition. The composition includes a therapeutically … |
ASTRAZENECA | 2023-08-11 | 2024-02-22 | |
| 113 | METHODS FOR TREATING SMALL CELL LUNG CANCER AND OTHER NEUROENDOCRINE CANCERS Related Patents View Abstract: The current disclosure provides novel therapeutic methods for treating SCLC and other neuroendocrine cancers by evaluating the biomarker SLFN11. Aspects of the disclosure relate … |
ASTRAZENECA | 2022-03-10 | 2024-02-22 | |
| 114 | PHARMACEUTICAL COMPOSITION Related Patents View Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid … |
ASTRAZENECA et. al. | 2023-10-10 | 2024-02-08 | |
| 115 | PHARMACEUTICAL COMPOSITION Related Patents View Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid … |
ASTRAZENECA et. al. | 2023-10-10 | 2024-02-08 | |
| 116 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS Citation: 2 Related Patents View Abstract: The present disclosure relates to methods for treating bronchiectasis, for example, non-cystic fibrosis bronchiectasis with compositions comprising an effective amount of certain … |
ASTRAZENECA; INSMED | 2023-08-15 | 2024-02-08 | |
| 117 | NEW METHOD TO PRONOSTIC LUNG CANCER Related Patents View Abstract: The present invention relates to the field of prognostic of lung cancer. In this study, the inventors used extensive gene expression profiling and flow cytometry for an … |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE et. al. | 2022-02-08 | 2024-02-08 | |
| 118 | ORAL FORMULATION OF A THERAPEUTIC COMPOUND Related Patents View Abstract: The present invention provides a pharmaceutical tablet formulation of tenapanor that is chemically stable and soluble comprising greater than about 6% w/w of amorphous tenapanor … |
ARDELYX et. al. | 2021-12-06 | 2024-02-08 | |
| 119 | COMBINATION TREATMENT Related Patents View Abstract: The present invention relates to methods for treating ischemic events in a patient, especially ST-segment elevation myocardial infarction and acute ischemic stroke, by … |
ASTRAZENECA | 2023-07-14 | 2024-01-25 | |
| 120 | TREATMENT OF FLARES IN LUPUS Related Patents View Abstract: The disclosure relates to methods and compositions for the treatment of Systemic Lupus Erythematosus (SLE). The disclosure particular relates to the treatment of flares in SLE … |
ASTRAZENECA | 2021-10-07 | 2024-01-25 | |
| 121 | CHEMICAL COMPOUNDS Related Patents View Abstract: The present invention relates to azaquinolone compounds of Formula (I), and their use in medicine. … |
ASTRAZENECA | 2023-09-14 | 2024-01-11 | |
| 122 | AUTOMATED ASSESSMENT OF WOUND TISSUE Related Patents View Abstract: A method of assessing a wound in a subject is provided. The method comprises obtaining one or more optical coherence tomography images of the wound and analysing the one or more … |
ASTRAZENECA | 2021-11-11 | 2024-01-04 | |
| 123 | N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)QUINOLINE-4-CARBOXAMIDES Related Patents View Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein R , R , R , R , R , and R are as defined in the specification; pharmaceutical … |
ASTRAZENECA | 2023-06-20 | 2023-12-21 | |
| 124 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF Related Patents View Abstract: The invention relates to a novel inhibitor pharmacophore of PCSK9 and heteroaryl compounds that bind the PCSK9 protein. … |
ASTRAZENECA | 2023-01-25 | 2023-12-21 | |
| 125 | Adjuvant Durvalumab in Combination with Chemotherapy for Treatment of Cancer Related Patents View Abstract: The disclosure generally relates to methods for treating cancer in a patient using durvalumab in combination with chemotherapy based on the patient’s minimal residual status. … |
ASTRAZENECA | 2021-10-11 | 2023-12-21 | |
| 126 | AMIDO HETEROAROMATIC COMPOUNDS Related Patents View Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to … |
ASTRAZENECA | 2023-05-18 | 2023-11-23 | |
| 127 | COMBINATION Related Patents View Abstract: The present invention features methods of treating cancer with an immunomodulatory agent, such as an anti-PD-L1 antibody or an antigen-binding fragment thereof, and an antisense … |
ASTRAZENECA | 2022-10-13 | 2023-11-23 | |
| 128 | COMBINATION THERAPY FOR TREATING CANCER Related Patents View Abstract: The present disclosure relates, in general, to therapeutic combinations, and to corresponding methods of treatment, pharmaceutical compositions, and kits. … |
ASTRAZENECA | 2021-10-07 | 2023-11-23 | |
| 129 | COMPOUNDS AND THEIR USE IN TREATING CANCER Related Patents View Abstract: The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where A, Z, Y, RA, Linker and v have any of the meanings defined … |
ASTRAZENECA | 2021-09-29 | 2023-11-23 | |
| 130 | BIOMARKERS FOR PREDICTING OVERALL SURVIVAL IN RECORRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA Related Patents View Abstract: The present disclosure generally relates to methods for treating head and neck squamous cell carcinoma patients based on use of blood-based tumor mutation burden, PD-L1 … |
ASTRAZENECA | 2021-05-12 | 2023-11-23 | |
| 131 | Arginase Inhibitors and Methods of Use Thereof Related Patents View Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the … |
ASTRAZENECA | 2023-07-10 | 2023-11-16 | |
| 132 | COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES Related Patents View Abstract: The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor … |
ASTRAZENECA | 2023-06-23 | 2023-11-16 | |
| 133 | ANTI-IFNAR1 DOSING REGIME FOR SUBCUTANEOUS INJECTION Related Patents View Abstract: The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease. Specifically, the disclosure relates to a subcutaneous dose of a type I IFN … |
ASTRAZENECA | 2023-04-21 | 2023-11-16 | |
| 134 | SPIROCYCLIC COMPOUNDS Related Patents View Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their … |
ASTRAZENECA | 2023-06-15 | 2023-11-09 | |
| 135 | PCSK9 INHIBITORS AND METHODS OF TREATMENT USING SAME Related Patents View Abstract: The present disclosure provides dosages and methods for treating a disease associated with proprotein convertase subtilisin/kexin type 9 (PCSK9). The present disclosure also … |
ASTRAZENECA | 2021-09-16 | 2023-11-09 | |
| 136 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTISENSE OLIGONUCLEOTIDE FOR ORAL ADMINISTRATION Related Patents View Abstract: A pharmaceutical composition comprising A) one or more ASO or a pharmaceutically acceptable salt thereof; B) one or more permeation enhancer; C) one or more optional … |
ASTRAZENECA et. al. | 2021-09-16 | 2023-11-09 | |
| 137 | METHODS FOR TREATING SEVERE ASTHMA IN PATIENTS WITH NASAL POLYPOSIS Related Patents View Abstract: Provided herein are methods of reducing exacerbations of asthma in an asthma patient with nasal polyposis, comprising administering to the patient an effective amount of the … |
ASTRAZENECA | 2023-03-27 | 2023-11-02 | |
| 138 | COMPOUNDS AND THEIR USE Related Patents View Abstract: The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R , R , R , R and R have the meanings … |
ASTRAZENECA et. al. | 2023-02-22 | 2023-11-02 | |
| 139 | ATR INHIBITORS FOR THE TREATMENT OF CANCER Related Patents View Abstract: This specification discloses the use of an ATR inhibitor, preferably in combination with a taxane, for the treatment of cancer in a particular subset of patients who have … |
ASTRAZENECA | 2021-05-10 | 2023-11-02 | |
| 140 | METHODS OF IMPROVING PROTEIN EXPRESSION Related Patents View Abstract: The present disclosure relates to nucleic acids that comprise a nucleotide sequence encoding an immunoglobulin heavy chain, wherein the nucleotide sequences of at one or two … |
ASTRAZENECA | 2021-07-02 | 2023-10-26 | |
| 141 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES Related Patents View Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X , R , R , R , R , R and R are as defined in the specification; … |
ASTRAZENECA | 2023-06-12 | 2023-10-05 | |
| 142 | BINDING MOLECULES AGAINST FRa Related Patents View Abstract: The present invention provides binding molecules (e.g. antibodies or antigen-binding fragments thereof) against FRα and related antibody-drug conjugates, along with pharmaceutical … |
ASTRAZENECA | 2023-03-02 | 2023-09-21 | |
| 143 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer Related Patents View Abstract: The specification generally relates to compounds of Formula (I): … |
ASTRAZENECA | 2023-02-21 | 2023-09-14 | |
| 144 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS Citation: 4 Related Patents View Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that … |
ASTRAZENECA | 2022-09-09 | 2023-09-07 | |
| 145 | METHODS FOR GENERATING PRIMARY IMMUNE CELLS Related Patents View Abstract: The disclosure relates to methods, cells, and compositions for preparing cell populations and compositions for adoptive cell therapy. In particular, provided herein are methods … |
ASTRAZENECA | 2022-08-23 | 2023-09-07 | |
| 146 | COMBINATION OF A BTK INHIBITOR AND AN INHIBITOR OF CDK9 TO TREAT CANCER Related Patents View Abstract: The present invention relates to combination of a BTK inhibitor and an inhibitor of CDK9 for use in the treatment of cancer in a subject. The BTK inhibitor can be acalabrutinib, … |
ASTRAZENECA | 2022-09-22 | 2023-08-17 | |
| 147 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS Citation: 4 Related Patents View Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that … |
ASTRAZENECA | 2023-04-13 | 2023-08-10 | |
| 148 | Dosage Regimen for the Treatment of Cancer Related Patents View Abstract: The present specification relates to AZD9833 for use in the treatment of cancer and methods of treatment of cancer involving administration of AZD9833 wherein, in each case, the … |
ASTRAZENECA | 2023-01-10 | 2023-08-10 | |
| 149 | OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER Related Patents View Abstract: The specification relates to osimertinib or a pharmaceutically acceptable salt thereof for use in the treatment of patients with locally advanced unresectable epidermal growth … |
ASTRAZENECA | 2023-03-28 | 2023-07-20 | |
| 150 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS Related Patents View Abstract: The present application relates to novel compounds of formula (I) to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to … |
ASTRAZENECA | 2023-02-27 | 2023-07-13 | |
| 151 | TUMOR MUTATIONAL BURDEN ASSOCIATED WITH SENSITIVITY TO IMMUNOTHERAPY IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA Related Patents View Abstract: The disclosure generally relates to methods for treating urothelial carcinoma patients based on use of PD-L1 expression, blood-based tumor mutation burden, and identification of … |
ASTRAZENECA | 2021-05-21 | 2023-06-22 | |
| 152 | LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS Related Patents View Abstract: Disclosed herein are compounds of Formula (I), Formula (III) or Formula (IIIa), or pharmaceutically acceptable salts thereof, wherein A, L, X , X , a, b, R and R are as defined … |
ASTRAZENECA | 2022-11-17 | 2023-06-15 | |
| 153 | ANTIBODY MOLECULES AND CONJUGATES Related Patents View Abstract: The present disclosure relates to antibody molecules that bind epidermal growth factor receptor (EGFR) and/or c-Met and conjugates containing these antibody molecules. The … |
ASTRAZENECA | 2022-11-09 | 2023-06-15 | |
| 154 | MEDICAMENT DISPENSING SYSTEM AND DISPENSING METHOD Related Patents View Abstract: A dispensing system ( ) and method for dispensing unit dosage forms ( ) from a blister pack ( ) is disclosed. The system ( ) comprises a housing ( ) for receiving a blister pack ( … |
ASTRAZENECA | 2022-06-08 | 2023-04-27 | |
| 155 | Arginase Inhibitors and Methods of Use Thereof Related Patents View Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the … |
ASTRAZENECA | 2022-07-15 | 2023-04-20 | |
| 156 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS Citation: 4 Related Patents View Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that … |
ASTRAZENECA | 2022-09-16 | 2023-04-13 | |
| 157 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS Citation: 4 Related Patents View Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that … |
ASTRAZENECA | 2022-09-10 | 2023-04-13 | |
| 158 | COMPOUNDS AND THEIR USE Related Patents View Abstract: The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R , R , R , R , R , W, X, Y, and Z have the meanings defined … |
ASTRAZENECA et. al. | 2022-07-01 | 2023-04-13 | |
| 159 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS Citation: 4 Related Patents View Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that … |
ASTRAZENECA | 2022-09-10 | 2023-03-23 | |
| 160 | COMPOUNDS AND THEIR USE Related Patents View Abstract: The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R , R , R , R and R have the meanings … |
ASTRAZENECA et. al. | 2021-12-07 | 2023-03-16 | |
| 161 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS Citation: 4 Related Patents View Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that … |
ASTRAZENECA | 2022-09-15 | 2023-03-02 | |
| 162 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS Citation: 4 Related Patents View Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that … |
ASTRAZENECA | 2022-09-09 | 2023-03-02 | |
| 163 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS Citation: 13 Related Patents View Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that … |
ASTRAZENECA | 2022-09-10 | 2023-02-02 | |
| 164 | [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases Related Patents View Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R , R and n have any of the meanings defined hereinbefore in the description; … |
ASTRAZENECA | 2022-06-29 | 2023-02-02 | |
| 165 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS Citation: 13 Related Patents View Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that … |
ASTRAZENECA | 2022-09-10 | 2023-01-26 | |
| 166 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS Citation: 13 Related Patents View Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that … |
ASTRAZENECA | 2022-09-10 | 2023-01-26 | |
| 167 | METHODS FOR PREVENTING OR TREATING CERTAIN DISORDERS BY INHIBITING BINDING OF IL-4 AND/OR IL-13 TO THEIR RESPECTIVE RECEPTORS Related Patents View Abstract: The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition … |
PIERIS PHARMACEUTICALS et. al. | 2022-06-14 | 2023-01-19 | |
| 168 | PHARMACEUTICAL COMPOSITION COMPRISING A POTENT INHIBITOR OF URAT1 Related Patents View Abstract: The present invention relates to pharmaceutical compositions containing 2-((3-(4-cyanonaphthalen-1-yl)pyridine-4-yl)thio)-2-methylpropanoic acid or a pharmaceutically acceptable … |
ARDEA BIOSCIENCES et. al. | 2022-06-23 | 2023-01-12 | |
| 169 | PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291 Related Patents View Abstract: The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical … |
ASTRAZENECA | 2022-04-26 | 2022-12-15 | |
| 170 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS Related Patents View Abstract: The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for … |
ASTRAZENECA et. al. | 2022-07-20 | 2022-12-01 | |
| 171 | LIPID NANOPARTICLES COMPRISING LIPOPHILIC ANTI-INFLAMMATORY AGENTS AND METHODS OF USE THEREOF Related Patents View Abstract: Disclosed herein are lipid nanoparticles comprising a lipid phase and at least one lipophilic anti-inflammatory agent, and pharmaceutical compositions comprising lipid … |
ASTRAZENECA | 2022-08-02 | 2022-11-24 | |
| 172 | METHODS AND COMBINATIONS FOR THE TREATMENT OF CANCER USING IMMUNE CHECKPOINT INHIBITOR ANTIBODIES Related Patents View Abstract: The disclosure relates to methods, compositions, and combinations for the treatment of cancer. Specifically, the disclosure relates to methods comprising administering to a … |
ASTRAZENECA | 2021-05-12 | 2022-11-17 | |
| 173 | TREATMENT OF LUPUS NEPHRITIS Citation: 1 Related Patents View Abstract: The disclosure relates to methods and compositions for the treatment of lupus nephritis. Specifically, the disclosure relates to methods comprising administering to a subject a … |
ASTRAZENECA | 2022-04-22 | 2022-11-03 | |
| 174 | CHEMICAL COMPOUNDS Related Patents View Abstract: Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the … |
ASTRAZENECA | 2022-04-27 | 2022-10-27 | |
| 175 | DOSE Citation: 1 Related Patents View Abstract: The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease. Specifically, the disclosure relates to a subcutaneous dose of a type I IFN … |
ASTRAZENECA | 2022-04-22 | 2022-10-27 | |
| 176 | CHEMICAL COMPOUNDS Related Patents View Abstract: The present invention relates to azaquinolone compounds of Formula (I), and their use in medicine. … |
ASTRAZENECA | 2022-04-07 | 2022-07-21 | |
| 177 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF Related Patents View Abstract: The invention relates to novel heteroaryl compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular … |
ASTRAZENECA | 2021-12-20 | 2022-07-14 | |
| 178 | PROTEIN KINASE B INHIBITORS Related Patents View Abstract: The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z , Z , R , R , R and n are as described in the specification, which may be useful … |
ASTRAZENECA | 2021-12-16 | 2022-07-14 | |
| 179 | ANTI-IL5R ANTIBODY FORMULATIONS Related Patents View Abstract: Provided herein are anti-IL5R antibody formulations containing an amount of surfactant below critical micelle concentration (CMC) of the surfactant and methods of using such … |
ASTRAZENECA | 2021-12-16 | 2022-06-23 | |
| 180 | IRAK4 INHIBITORS Related Patents View Abstract: The present application relates to chemical compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit IRAK4 and consequently have potential utility in … |
ASTRAZENECA | 2021-12-01 | 2022-06-16 | |
| 181 | OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER Related Patents View Abstract: The specification relates to osimertinib or a pharmaceutically acceptable salt thereof for use in the treatment of patients with locally advanced unresectable epidermal growth … |
ASTRAZENECA | 2021-10-27 | 2022-06-16 | |
| 182 | MPO INHIBITORS FOR USE IN MEDICINE Related Patents View Abstract: The present disclosure relates to new therapeutic uses of MPO inhibitors and methods of treatment involving the same. … |
ASTRAZENECA | 2021-12-02 | 2022-05-26 | |
| 183 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS Citation: 14 Related Patents View Abstract: The present disclosure relates to methods for treating bronchiectasis, for example, non-cystic fibrosis bronchiectasis with compositions comprising an effective amount of certain … |
ASTRAZENECA et. al. | 2022-01-14 | 2022-05-05 | |
| 184 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS Related Patents View Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their … |
ASTRAZENECA | 2021-10-05 | 2022-04-28 | |
| 185 | Automated Detection of Safety Signals for Pharmacovigilance Citation: 2 Related Patents View Abstract: An embodiment may involve obtaining a set of pre-defined features and a new document; extracting a subset of the pre-defined features from within new document; applying a natural … |
ASTRAZENECA | 2021-07-22 | 2022-03-31 | |
| 186 | METHOD OF TREATING FATTY LIVER DISEASE Related Patents View Abstract: The present disclosure provides methods of treating or preventing fatty liver disease and/or lowering cholesterol and LDL cholesterol levels in a subject. The present disclosure … |
ASTRAZENECA et. al. | 2021-09-21 | 2022-03-24 | |
| 187 | Compositions and Methods for Treating Late Stage Lung Cancer Related Patents View Abstract: Disclosed are methods for treating late stage (e.g., clinical stage III or IV), unresectable non-small-cell lung cancer (NSCLC) with an antibody that inhibits PD1/PD-L1 activity … |
ASTRAZENECA | 2021-11-18 | 2022-03-10 | |
| 188 | COMBINATION TREATMENT Related Patents View Abstract: The present invention relates to methods for treating ischemic events in a patient, especially ST-segment elevation myocardial infarction and acute ischemic stroke, by … |
ASTRAZENECA | 2021-08-18 | 2022-03-10 | |
| 189 | METHODS OF TREATING HOMOLOGOUS RECOMBINATION DEFICIENT CANCER Citation: 4 Related Patents View Abstract: This disclosure relates to methods of treating homologous recombination (HR) deficient cancers, such as ovarian cancer, fallopian tube cancer, primary peritoneal cancer, breast … |
ASTRAZENECA | 2021-08-11 | 2022-02-17 | |
| 190 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer Related Patents View Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where R and R have any of the meanings defined herein. The … |
ASTRAZENECA | 2021-08-27 | 2022-02-10 | |
| 191 | METHODS OF DELAYING PAIN PROGRESSION AND TREATING PROSTATE CANCER Related Patents View Abstract: This disclosure relates to methods for delaying pain progression in a subject receiving treatment for prostate cancer. This disclosure further relates to methods for treating … |
ASTRAZENECA | 2021-08-03 | 2022-02-10 | |
| 192 | COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES Citation: 1 Related Patents View Abstract: The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor … |
ASTRAZENECA | 2021-07-09 | 2022-01-27 | |
| 193 | METHODS OF TREATING CHRONIC KIDNEY DISEASE WITH DAPAGLIFLOZIN Citation: 2 Related Patents View Abstract: The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as … |
ASTRAZENECA | 2021-06-14 | 2022-01-27 | |
| 194 | CHEMICAL COMPOUNDS Citation: 1 Related Patents View Abstract: The present invention relates to azaquinolone compounds of Formula (I), and their use in medicine. … |
ASTRAZENECA | 2021-06-22 | 2022-01-13 | |
| 195 | Classification of Immuno-Oncology Impact Related Patents View Abstract: An embodiment may involve reading conditions for respectively determining research impacts of cancer-related journal publications, congress activities, guideline activities, and … |
ASTRAZENECA | 2021-06-02 | 2021-12-16 | |
| 196 | METHODS FOR TREATING SEVERE ASTHMA IN PATIENTS WITH NASAL POLYPOSIS Related Patents View Abstract: Provided herein are methods of reducing exacerbations of asthma in an asthma patient with nasal polyposis, comprising administering to the patient an effective amount of the … |
ASTRAZENECA | 2021-06-04 | 2021-12-09 | |
| 197 | 2,3-DIHYDROISOINDOLE-1-CARBOXAMIDES USEFUL AS ROR-GAMMA MODULATORS Related Patents View Abstract: The present specification provides a compound of formula (I): … |
ASTRAZENECA | 2021-05-07 | 2021-12-09 | |
| 198 | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER Related Patents View Abstract: The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the adjuvant treatment after tumour resection of patients with … |
ASTRAZENECA | 2021-05-25 | 2021-12-02 | |
| 199 | METHODS AND COMBINATIONS FOR THE TREATMENT OF CANCER USING IMMUNE CHECKPOINT INHIBITOR ANTIBODIES Related Patents View Abstract: The disclosure relates to methods, compositions, and combinations for the treatment of cancer. Specifically, the disclosure relates to methods comprising administering to a … |
ASTRAZENECA | 2021-05-12 | 2021-11-18 | |
| 200 | Deuterated Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer Related Patents View Abstract: The specification generally relates to compounds of Formula (I): … |
ASTRAZENECA | 2021-07-20 | 2021-11-11 |